Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, June 4, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:
DND; OTC: CPHMF), announced today that Larry Andrews, President and
Chief Executive Officer, is presenting at the Bloom & Burton Healthcare
Investor Conference, which is being held in Toronto on June 21 at the
Toronto Board of Trade. Mr. Andrews will provide a corporate update and
participate in a Q&A breakout session at 3:30 PM ET in room C/D.
Cipher's presentation will be available on their website www.cipherpharma.com.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty
pharmaceutical company that commercializes novel formulations of
successful, currently marketed molecules. Cipher's strategy is to
in-license clearly differentiated products, advance them through the
clinical development and regulatory approval stages, and out-license to
international marketing partners. The Company's first product is a
fenofibrate formulation marketed in the United States as Lipofen®.
Cipher's second product, an extended-release tramadol, is marketed in
the United States as ConZip™ and is marketed in Canada as Durela™.
Cipher's third product, a novel formulation of the acne treatment
isotretinoin, was recently approved by the FDA and is expected to be
launched in Q4 2012 as Absorica™. The product is also currently being
reviewed by Health Canada. For more information, please visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
For further information:
The Equicom Group
(416) 815-0700 ext 278
(416) 815-0080 fax
President and CEO
(905) 602-5840 ext 324
(905) 602-0628 fax